DAWN — Day One Biopharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $1.36bn
- $992.49m
- 22
- 18
- 77
- 33
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 27.3 | 43.7 | 284 | 342 | 366 |
Prepaid Expenses | |||||
Total Current Assets | 27.3 | 45.1 | 289 | 348 | 375 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 0.483 | 0.284 | 0.719 | 0.56 |
Long Term Investments | |||||
Total Assets | 27.3 | 45.7 | 290 | 349 | 376 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.02 | 2 | 8.66 | 16.6 | 29.5 |
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.51 | 7.9 | 8.67 | 17 | 29.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 19.8 | 37.8 | 281 | 332 | 347 |
Total Liabilities & Shareholders' Equity | 27.3 | 45.7 | 290 | 349 | 376 |
Total Common Shares Outstanding |